

Supplementary Material for

**Contribution of protein phosphorylation to binding induced folding of the
SLBP-histone mRNA complex probed by phosphorus-31 NMR**

Roopa Thapar




Figure S1. A temperature titration of the SLBP-RNA complex was performed between 15°C – 55°C on an Inova 500 MHz spectrometer as described under “Methods”. Integration of NMR peak intensities and lineshape analysis confirms that resonances from the bound form (at ~20 p.p.m) exchange only with the upfield shifted resonances corresponding to free SLBP.





Figure S2. A pH titration of the SLBP-RNA complex shows the response of the ^{31}P nucleus in both the free and bound forms of SLBP to pH. The change in chemical shift was plotted vs. pH as shown above. The two peaks corresponding to the RNA-bound forms are shown in open and filled circles (\bullet, \circ) whereas the titration of the upfield shifted resonance corresponding to free SLBP is shown in filled squares (\blacksquare).




Figure S3. ^{31}P NMR spectrum of the free RNA collected with identical spectral parameters as for the protein-RNA complex. No resonance is observed at +20.3 p.p.m. indicating that the resonances we observe in the complex do not arise from a sample impurity in the RNA.




Figure S4. In black is shown the ^{31}P spectrum of the SLBP-RNA complex without urea. In red is shown the spectrum in the presence of 6 M urea. Changes in peak intensities are observed for the resonances in the complex, the free RNA, and free SLBP.

Supplementary Table 1. O-P-O bond angles measured for phosphothreonine in 74 crystal structures

| PDB Code | Structure | O-P-O ANGLES |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| 4QOZ | Crystal structure of the histone mRNA stem-loop, stem-loop binding protein (phosphorylated), and 3'hExo ternary complex | 107.64, 109.95, 110.64, 109.92 |
| 4PSW | Crystal structure of histone acetyltransferase complex | 113.15, 105.42, 105.59, 112.89 |
| 4UN0 | Crystal structure of the human CDK12-cyclinK complex | 109.27, 109.52, 109.50, 109.52 |
| 4KUJ | Structural and functional characterization of a novel Alpha Kinase from Entamoeba histolytica | 104.71, 114.36, 114.62, 101.21 |
| 4O21 | Product complex of metal-free PKAc, ATP-gamma-S and SP20. | 110.14, 110.73, 108.30, 109.09 |
| 4CXA | Crystal structure of the human CDK12-cyclin K complex bound to AMPPNP | 108.90, 109.37, 109.70, 109.71 |
| 4O0M | Crystal structure of T. Elongatus BP-1 Clock Protein KaiC | 109.19, 109.34, 109.38, 109.22 |
| 4OGR | crystal structure of P-TEFb complex with AFF4 and Tat | 108.60, 109.04, 110.14, 110.01 |
| 3WG7 | A 1.9 angstrom radiation damage free X-ray structure of large (420KDa) protein by femtosecond crystallography | 108.97, 106.74, 112.98, 105.47 |
| 4OR5 | Crystal structure of HIV-1 Tat complexed with human P-TEFb and AFF4 | 111.73, 107.92, 106.86, 111.90 |
| 4BN1 | Crystal structure of V174M mutant of Aurora-A kinase | 107.20, 107.53, 113.91, 113.92 |
| 4JS8 | Crystal structure of TTK kinase domain with an inhibitor: 401348 | (phos #1) 109.49, 110.46, 107.96, 106.66 (phos #2) 108.80, 108.21, 109.75, 108.66 |
| 4NM5 | Crystal structure of GSK-3/Axin complex bound to phosphorylated Wnt receptor LRP6 c-motif | 108.84, 109.73, 109.81, 109.61 |
| 4NST | Crystal structure of human Cdk12/Cyclin K in complex with ADP-aluminum fluoride | 105.72, 105.88, 115.27, 109.64 |
| 4CRS | Human Protein Kinase N2 (PKN2, PRKCL2) in complex with ATPgammaS | (phos #1) 103.57, 100.87, 118.01, 113.55 (phos #2) 105.92, 117.09, 103.64, 112.54 |
| 4C2V | Aurora B kinase in complex with the specific inhibitor Barasertib | 109.58, 103.13, 115.75, 113.86 |
| 4C2W | Crystal structure of Aurora B in complex with | 109.20, 100.31, 112.17, |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| | AMP-PNP | 118.10 |
| 4OA2 | Crystal structure of the BRI1 kinase domain (865-1196) in complex with ADP from <i>Arabidopsis thaliana</i> | 102.34, 104.00, 115.38, 114.98 |
| 4OA9 | Crystal structure of the BRI1 kinase domain (865-1160) in complex with AMPPNP and Mn from <i>Arabidopsis thaliana</i> | 110.51, 101.23, 115.99, 112.19 |
| 4OAB | Crystal structure of the BRI1 kinase domain (865-1160) in complex with ATP from <i>Arabidopsis thaliana</i> | 117.33, 102.61, 104.80, 110.78 |
| 4OAC | Crystal structure of the BRI1 kinase domain (865-1160) in complex with ADP from <i>Arabidopsis thaliana</i> | 103.22, 113.01, 104.48, 110.59 |
| 4JDJ | Crystal structure of Serine/threonine-protein kinase PAK 4 F461V mutant in complex with Paktide T peptide substrate | 114.41, 113.22, 104.49, 105.08 |
| 4JDK | Crystal structure of Serine/threonine-protein kinase PAK 4 F461V mutant in complex with Paktide S peptide substrate | 101.03, 112.50, 112.85, 104.96 |
| 4CFE | Structure of full length human AMPK in complex with a small molecule activator, a benzimidazole derivative (991) | 109.23, 109.36, 109.29, 109.38 |
| 4CFF | Structure of full length human AMPK in complex with a small molecule activator, a thienopyridone derivative (A-769662) | 108.59, 109.59, 109.49, 109.60 |
| 4CFH | Structure of an active form of mammalian AMPK | 109.54, 110.11, 110.06, 108.16 |
| 4CFN | Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. | 105.37, 105.55, 104.98, 115.92 |
| 4CFW | Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. | 115.81, 104.62, 115.00, 110.55 |
| 4IB0 | X-ray Structure of cAMP dependent protein kinase A in complex with high Na ⁺ concentration, ADP and phosphorylated peptide pSP20 | 109.14, 108.85, 107.25, 112.50 |
| 4IB1 | Structure of cAMP dependent protein kinase A in complex with high K ⁺ concentration, ADP and phosphorylated peptide pSP20 | 109.72, 110.05, 110.02, 109.48 |
| 4IB3 | Structure of cAMP dependent protein kinase A in complex with ADP, phosphorylated peptide pSP20, and no metal | 109.69, 109.35, 109.85, 109.25 |
| 4LKL | Crystal structure of Plk1 Polo-box domain in complex with PL-55 | 102.15, 101.36, 112.39, 113.88 |
| 4LKM | Crystal structure of Plk1 Polo-box domain in | 114.17, 114.23, 103.58, |

| | | |
|------|-----------------------------------------------------------------------------------------------------|--------------------------------|
| 4LKM | Crystal structure of Plk1 Polo-box domain in complex with PL-74 | 114.17, 114.23, 103.58, 107.53 |
| 4C4E | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | 112.56, 116.09, 109.32, 104.53 |
| 4C4F | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | 113.99, 113.18, 107.12, 108.12 |
| 4C4G | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | 108.77, 112.75, 113.42, 106.35 |
| 4C4J | Structure-based design of orally bioavailable pyrrolopyridine inhibitors of the mitotic kinase MPS1 | 105.99, 108.81, 112.99, 111.69 |
| 4LPA | Crystal structure of a Cdc6 phosphopeptide in complex with Cks1 | 109.34, 107.78, 107.90, 111.93 |
| 4N7T | Crystal structure of phosphorylated phosphopentomutase from streptococcus mutans | 108.47, 109.97, 112.48, 107.62 |
| 4M69 | Crystal structure of the mouse RIP3-MLKL complex | 114.24, 104.46, 114.53, 103.77 |
| 4BU0 | Crystal structure of Rad4 BRCT1,2 in complex with a Crb2 phosphopeptide | 111.60, 118.92, 103.62, 112.68 |
| 4BU1 | Crystal structure of Rad4 BRCT1,2 in complex with a Crb2 phosphopeptide | 108.42, 108.26, 109.77, 110.61 |
| 4C33 | PKA-S6K1 Chimera Apo | 111.09, 103.53, 105.13, 111.26 |
| 4C34 | PKA-S6K1 Chimera with Staurosporine bound | 107.24, 113.09, 108.17, 107.89 |
| 4C35 | PKA-S6K1 Chimera with compound 1 (NU1085) bound | 109.78, 107.66, 109.82, 113.13 |
| 4C36 | PKA-S6K1 Chimera with compound 15e (CCT147581) bound | 117.23, 104.54, 108.31, 109.80 |
| 4C37 | PKA-S6K1 Chimera with compound 21a (CCT196539) bound | 108.65, 108.28, 115.96, 112.20 |
| 4C38 | PKA-S6K1 Chimera with compound 21e (CCT239066) bound | 108.22, 109.75, 113.22, 110.53 |
| 4L1U | Crystal Structure of Human Rtf1 Plus3 Domain in Complex with Spt5 CTR Phosphopeptide | 109.75, 110.46, 108.68, 109.01 |
| 4BL0 | Crystal structure of yeast Bub3-Bub1 bound to phospho-Spc105 | 109.20, 108.76, 108.77, 110.31 |
| 4EQC | Crystal structure of PAK1 kinase domain in complex with FRAX597 inhibitor | 100.21, 117.12, 106.44, 112.68 |
| 4JG1 | Structure of phosphoserine/threonine (pSTAb) | 112.06, 107.42, 112.73, |

| | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| 4IMI | Novel Modifications on C-terminal Domain of RNA Polymerase II can Fine-tune the Phosphatase Activity of Ssu72. | 114.73, 108.11, 104.07, 109.94 |
| 4LR7 | Phosphopentomutase S154A variant | 106.52, 101.82, 114.90, 113.91 |
| 4LR8 | Phosphopentomutase S154A variant soaked with ribose 5-phosphate | 114.22, 114.86, 107.70, 104.01 |
| 4LR9 | Phosphopentomutase S154A variant soaked with 2,3-dideoxyribose 5-phosphate | 107.57, 113.40, 114.23, 101.69 |
| 4LRA | Phosphopentomutase S154G variant | 107.71, 102.85, 114.86, 101.36 |
| 4LRB | Phosphopentomutase S154G variant soaked with 2,3-dideoxyribose 5-phosphate | 106.81, 102.42, 113.99, 114.64 |
| 4LRC | Phosphopentomutase V158L variant | 100.74, 106.20, 106.63, 115.09 |
| 4LRD | Phosphopentomutase 4H11 variant | 89.49, 125.64, 127.77, 91.58 |
| 4LRE | Phosphopentomutase soaked with 2,3-dideoxyribose 5-phosphate | 113.86, 106.73, 103.81, 114.06 |
| 4LRF | Phosphopentomutase S154G variant soaked with ribose 5-phosphate | 113.31, 114.85, 107.24, 102.12 |
| 4KAV | Crystal Structure of the soluble domain of Lipooligosaccharide phosphoethanolamine transferase A from Neisseria meningitidis | 110.36, 107.69, 110.15, 116.30 |
| 4L46 | Crystal structures of human p70S6K1-WT | 111.79, 107.01, 107.37, 111.05 |
| 4KAY | Structure of the soluble domain of Lipooligosaccharide phosphoethanolamine transferase A from Neisseria meningitidis - complex with Zn | 110.85, 107.44, 114.70, 110.99 |
| 4B8M | Aurora B kinase in complex with VX-680 | 113.87, 104.21, 102.45, 113.92 |
| 3UEO | Crystal structure of TopBP1 BRCT4/5 domains in complex with a phospho-peptide | 108.75, 109.02, 106.80, 109.28 |
| 4IAC | X-RAY structure of cAMP dependent protein kinase A in complex with HIGH Mg ²⁺ concentration, AMP-PCP AND pseudo-substrate peptide SP20 | 109.70, 109.54, 109.69, 109.28 |
| 4IAD | Low temperature X-ray Structure OF cAMP dependent protein kinase A in complex with high Mg ²⁺ concentration, ADP and phosphorylated peptide pSP20 | 111.64, 108.47, 111.65, 108.06 |
| 4IAF | Room temperature X-ray Structure OF cAMP dependent protein kinase A in complex with high Mg ²⁺ concentration, ADP and | 109.19, 109.73, 109.12, 109.71 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| 4IAF | Room temperature X-ray Structure OF cAMP dependent protein kinase A in complex with high Mg ²⁺ concentration, ADP and phosphorylated peptide pSP20 | 109.19, 109.73, 109.12, 109.71 |
| 4IAI | X-ray Structure of cAMP dependent protein kinase A in complex with high Ca ²⁺ concentration, ADP and phosphorylated peptide pSP20 | 108.79, 109.76, 109.79, 107.80 |
| 4IAK | Low temperature X-ray structure of cAMP dependent protein kinase A in complex with high Sr ²⁺ concentration, ADP and phosphorylated peptide pSP20 | 109.91, 111.02, 110.09, 107.16 |
| 4IAY | Room temperature X-ray Structure of cAMP dependent protein kinase A in complex with high Sr ²⁺ concentration, ADP and phosphorylated peptide pSP20 | 110.08, 110.03, 108.58, 108.93 |